BR0315995A - Compound, use of a compound pharmaceutical composition, methods for the therapy of pain, gastrointestinal disorders, and anxiety in a warm-blooded animal, and process for preparing a compound - Google Patents
Compound, use of a compound pharmaceutical composition, methods for the therapy of pain, gastrointestinal disorders, and anxiety in a warm-blooded animal, and process for preparing a compoundInfo
- Publication number
- BR0315995A BR0315995A BR0315995-7A BR0315995A BR0315995A BR 0315995 A BR0315995 A BR 0315995A BR 0315995 A BR0315995 A BR 0315995A BR 0315995 A BR0315995 A BR 0315995A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- therapy
- pain
- anxiety
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 208000002193 Pain Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 208000019901 Anxiety disease Diseases 0.000 title abstract 2
- 208000018522 Gastrointestinal disease Diseases 0.000 title abstract 2
- 230000036506 anxiety Effects 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
"COMPOSTO, USO DE UM COMPOSTO COMPOSIçãO FARMACêUTICA, MéTODOS PARA A TERAPIA DA DOR, DE DISTúRBIOS GASTROINTESTINAIS, E DA ANSIEDADE EM UM ANIMAL DE SANGUE QUENTE, E, PROCESSO PARA PREPARAR UM COMPOSTO". Compostos da fórmula geral (I) em que R~ 1~, R~ 2~ e R~ 3~ são como definidos na especificação, assim como sais, enanciómeros dos mesmos e composições farmacêuticas, que incluem os compostos, são preparados. Eles são úteis em terapia, em particular no controle da dor."COMPOUND, USE OF A PHARMACEUTICAL COMPOSITION, METHODS FOR PAIN THERAPY, GASTROINTESTINAL DISORDERS, AND ANXIETY IN A HOT BLOOD ANIMAL, AND PROCESS TO PREPARE A COMPOUND." Compounds of the general formula (I) wherein R 1, R 2 and R 3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions, including the compounds, are prepared. They are useful in therapy, particularly in pain management.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0203303A SE0203303D0 (en) | 2002-11-07 | 2002-11-07 | Novel Compounds |
PCT/SE2003/001707 WO2004041802A1 (en) | 2002-11-07 | 2003-11-05 | 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0315995A true BR0315995A (en) | 2005-09-27 |
Family
ID=20289507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0315995-7A BR0315995A (en) | 2002-11-07 | 2003-11-05 | Compound, use of a compound pharmaceutical composition, methods for the therapy of pain, gastrointestinal disorders, and anxiety in a warm-blooded animal, and process for preparing a compound |
Country Status (20)
Country | Link |
---|---|
US (2) | US7253173B2 (en) |
EP (1) | EP1562924A1 (en) |
JP (1) | JP4528128B2 (en) |
KR (1) | KR20050072482A (en) |
CN (1) | CN100415729C (en) |
AR (1) | AR041895A1 (en) |
AU (1) | AU2003278665B2 (en) |
BR (1) | BR0315995A (en) |
CA (1) | CA2502732A1 (en) |
IS (1) | IS7863A (en) |
MX (1) | MXPA05004708A (en) |
NO (1) | NO20052698D0 (en) |
NZ (1) | NZ539484A (en) |
PL (1) | PL376894A1 (en) |
RU (1) | RU2005111985A (en) |
SE (1) | SE0203303D0 (en) |
TW (1) | TW200418822A (en) |
UA (1) | UA80988C2 (en) |
WO (1) | WO2004041802A1 (en) |
ZA (1) | ZA200503556B (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ539828A (en) * | 2001-05-18 | 2007-01-26 | Astrazeneca Ab | 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders |
SE0203302D0 (en) * | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Compounds |
SE0203300D0 (en) | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Compounds |
SE0203301D0 (en) * | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Compounds |
SE0203303D0 (en) * | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Compounds |
JP4976134B2 (en) | 2003-10-01 | 2012-07-18 | アドラー コーポレーション | Spirocyclic heterocyclic derivatives and methods of using them |
SE0400027D0 (en) * | 2004-01-09 | 2004-01-09 | Astrazeneca Ab | Diarylmethyl piperazine derivatives, preparations thereof and uses thereof |
MX2007001240A (en) | 2004-08-02 | 2007-03-23 | Astrazeneca Ab | Diarylmethyl piperazine derivatives, preparations thereof and uses thereof. |
SE0401968D0 (en) * | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Diarylmethyl piperazine derivatives, preparations thereof and uses thereof |
US7598261B2 (en) | 2005-03-31 | 2009-10-06 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
TW200803856A (en) | 2005-09-02 | 2008-01-16 | Mount Cook Biosciences Inc | Method of treating parkinson's disease with diarylmethylpiperazine compounds exhibiting delta receptor agonist activity |
US7576207B2 (en) | 2006-04-06 | 2009-08-18 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
KR101288781B1 (en) | 2006-06-28 | 2013-07-22 | 암젠 인크 | Glycine transporter-1 inhibitors |
CN102065860A (en) * | 2008-05-20 | 2011-05-18 | 阿斯利康(瑞典)有限公司 | Method of treating anxious major depressive disorder |
US10973815B2 (en) | 2016-03-31 | 2021-04-13 | Versi Group, Llc | Delta opioid agonist mu opioid antagonist compositions and methods for treating Parkinsons disease |
EP3681492A4 (en) * | 2017-09-05 | 2021-03-17 | The Royal Institution for the Advancement of Learning / McGill University | Compounds, pharmaceutical compositions and use thereof as inhibitors of ran gtpase |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH583713A5 (en) * | 1973-06-29 | 1977-01-14 | Cermol Sa | |
DE2900810A1 (en) | 1979-01-11 | 1980-07-24 | Cassella Ag | Antidepressant N-benzhydryl-N'-hydroxy-benzyl-piperazine derivs. - prepd. e.g. by reductive alkylation of N-benzhydryl-piperazine cpds. with 4-hydroxy-benzaldehyde |
IT1140978B (en) | 1980-05-23 | 1986-10-10 | Selvi & C Spa | 1- (4-CHLOROBENZIDRIL) -4- (2,3-DIIDROS SIPROPIL) -PIPERAZINE, METHODS FOR ITS PREPARATION AND RELATED PHARMACEUTICAL COMPOSITION |
GB8320701D0 (en) | 1983-08-01 | 1983-09-01 | Wellcome Found | Chemotherapeutic agent |
IT1196150B (en) | 1984-06-19 | 1988-11-10 | Poli Ind Chimica Spa | DERIVATIVES OF 1- (BIS- (4-FLUOROFENIL) METHYL) -4- (3-FENYL-2-PROPENYL) -HESHYDRO-1H-1,4-DIAZEPIN ACTIVATED CALCIUM ANTAGONIST, ITS PREPARATION AND COMPOSITIONS THAT CONTAIN IT |
SE8500573D0 (en) | 1985-02-08 | 1985-02-08 | Ferrosan Ab | NOVEL PIPERAZINECARBOXAMIDES HAVING A PHENOXYALKYL OR THIOPHENOXYALKYL SIDE CHAIN |
US5028610A (en) | 1987-03-18 | 1991-07-02 | Sankyo Company Limited | N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use |
US4829065A (en) | 1987-04-24 | 1989-05-09 | Syntex Pharmaceuticals, Ltd. | Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives |
US4826844A (en) | 1987-09-30 | 1989-05-02 | American Home Products Corporation | Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols |
US5840896A (en) * | 1989-11-22 | 1998-11-24 | Janssen Pharmaceutica, N.V. | Method of preventing or limiting reperfusion damage |
IL96390A (en) | 1989-11-22 | 1995-06-29 | Janssen Pharmaceutica Nv | Pharmaceutical compositions comprising n-alkylpiperazine-alkanamide derivatives for preventing or limiting reperfusion damage and some such novel compounds and their preparation |
EP0546102B1 (en) | 1990-08-29 | 1997-10-15 | PHARMACIA & UPJOHN COMPANY | Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases |
KR970005927B1 (en) | 1990-10-10 | 1997-04-22 | 쉐링 코포레이션 | Pyridine and dyridine n-oxide derivatives of diaryl methyl piperidines or piperazines, and compositions and process for preparation thereof |
GB9202238D0 (en) | 1992-02-03 | 1992-03-18 | Wellcome Found | Compounds |
US5985880A (en) | 1996-06-05 | 1999-11-16 | Delta Pharmaceuticals | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
US5574159A (en) * | 1992-02-03 | 1996-11-12 | Delta Pharmaceuticals, Inc. | Opioid compounds and methods for making therefor |
US5681830A (en) * | 1992-02-03 | 1997-10-28 | Delta Pharmaceuticals, Inc. | Opioid compounds |
US5807858A (en) * | 1996-06-05 | 1998-09-15 | Delta Pharmaceutical, Inc. | Compositions and methods for reducing respiratory depression |
FR2696744B1 (en) | 1992-10-12 | 1994-12-30 | Logeais Labor Jacques | 2-Pyrrolidone derivatives, their preparation process and their therapeutic applications. |
RU2124511C1 (en) | 1993-05-14 | 1999-01-10 | Фармасьютикал Ко., Лтд | Piperazine derivatives |
JPH09501156A (en) | 1993-07-30 | 1997-02-04 | ザ.ウェルカム.ファウンデーション.リミテッド | Piperazine compounds for use in therapy |
JP3352184B2 (en) | 1993-11-12 | 2002-12-03 | 株式会社アズウェル | Piperazine unsaturated fatty acid derivative |
IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
SE9504661D0 (en) * | 1995-12-22 | 1995-12-22 | Astra Pharma Inc | New compounds |
SE9604786D0 (en) | 1996-12-20 | 1996-12-20 | Astra Pharma Inc | New compounds |
TW548271B (en) | 1996-12-20 | 2003-08-21 | Astra Pharma Inc | Novel piperidine derivatives having an exocyclic double bond with analgesic effects |
CA2316341A1 (en) | 1997-12-24 | 1999-07-08 | Ortho-Mcneil Pharmaceutical, Inc. | 4-[aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor |
US6011035A (en) | 1998-06-30 | 2000-01-04 | Neuromed Technologies Inc. | Calcium channel blockers |
SE9904675D0 (en) | 1999-12-20 | 1999-12-20 | Astra Pharma Inc | Novel compounds |
SE9904674D0 (en) | 1999-12-20 | 1999-12-20 | Astra Pharma Inc | Novel compounds |
SE9904673D0 (en) * | 1999-12-20 | 1999-12-20 | Astra Pharma Inc | Novel compounds |
SE0001209D0 (en) | 2000-04-04 | 2000-04-04 | Astrazeneca Canada Inc | Novel compounds |
SE0101766D0 (en) | 2001-05-18 | 2001-05-18 | Astrazeneca Ab | Novel compounds |
SE0101765D0 (en) | 2001-05-18 | 2001-05-18 | Astrazeneca Ab | Novel compounds |
NZ539828A (en) * | 2001-05-18 | 2007-01-26 | Astrazeneca Ab | 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders |
SE0103313D0 (en) | 2001-10-03 | 2001-10-03 | Astrazeneca Ab | Novel compounds |
PL371297A1 (en) * | 2001-10-29 | 2005-06-13 | Ardent Pharmaceuticals, Inc. | Method of treating depression with delta receptor agonist compounds |
US8476280B2 (en) | 2002-05-09 | 2013-07-02 | Versi Group, Llc | Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists |
SE0203303D0 (en) | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Compounds |
SE0203302D0 (en) | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Compounds |
SE0203300D0 (en) | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Compounds |
SE0300105D0 (en) | 2003-01-16 | 2003-01-16 | Astrazeneca Ab | Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof |
SE0400027D0 (en) * | 2004-01-09 | 2004-01-09 | Astrazeneca Ab | Diarylmethyl piperazine derivatives, preparations thereof and uses thereof |
SE0401968D0 (en) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Diarylmethyl piperazine derivatives, preparations thereof and uses thereof |
MX2007001240A (en) * | 2004-08-02 | 2007-03-23 | Astrazeneca Ab | Diarylmethyl piperazine derivatives, preparations thereof and uses thereof. |
CN101128447A (en) | 2005-02-28 | 2008-02-20 | 阿斯利康(瑞典)有限公司 | Diarylmethyl piperazine derivatives, preparations thereof and uses thereof |
CN102065860A (en) * | 2008-05-20 | 2011-05-18 | 阿斯利康(瑞典)有限公司 | Method of treating anxious major depressive disorder |
-
2002
- 2002-11-07 SE SE0203303A patent/SE0203303D0/en unknown
-
2003
- 2003-05-11 UA UAA200503862A patent/UA80988C2/en unknown
- 2003-11-04 TW TW092130836A patent/TW200418822A/en unknown
- 2003-11-05 PL PL376894A patent/PL376894A1/en not_active Application Discontinuation
- 2003-11-05 RU RU2005111985/04A patent/RU2005111985A/en not_active Application Discontinuation
- 2003-11-05 JP JP2004549776A patent/JP4528128B2/en not_active Expired - Fee Related
- 2003-11-05 CN CNB200380102831XA patent/CN100415729C/en not_active Expired - Fee Related
- 2003-11-05 EP EP03770198A patent/EP1562924A1/en not_active Withdrawn
- 2003-11-05 NZ NZ539484A patent/NZ539484A/en unknown
- 2003-11-05 WO PCT/SE2003/001707 patent/WO2004041802A1/en active Application Filing
- 2003-11-05 US US10/533,654 patent/US7253173B2/en not_active Expired - Fee Related
- 2003-11-05 AR ARP030104053A patent/AR041895A1/en unknown
- 2003-11-05 MX MXPA05004708A patent/MXPA05004708A/en active IP Right Grant
- 2003-11-05 KR KR1020057008061A patent/KR20050072482A/en not_active Application Discontinuation
- 2003-11-05 AU AU2003278665A patent/AU2003278665B2/en not_active Ceased
- 2003-11-05 BR BR0315995-7A patent/BR0315995A/en not_active IP Right Cessation
- 2003-11-05 CA CA002502732A patent/CA2502732A1/en not_active Abandoned
-
2005
- 2005-05-04 ZA ZA200503556A patent/ZA200503556B/en unknown
- 2005-05-25 IS IS7863A patent/IS7863A/en unknown
- 2005-06-06 NO NO20052698A patent/NO20052698D0/en not_active Application Discontinuation
-
2007
- 2007-07-09 US US11/774,935 patent/US7960389B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7960389B2 (en) | 2011-06-14 |
JP4528128B2 (en) | 2010-08-18 |
PL376894A1 (en) | 2006-01-09 |
KR20050072482A (en) | 2005-07-11 |
WO2004041802A1 (en) | 2004-05-21 |
WO2004041802A8 (en) | 2005-03-10 |
JP2006514002A (en) | 2006-04-27 |
NO20052698L (en) | 2005-06-06 |
TW200418822A (en) | 2004-10-01 |
RU2005111985A (en) | 2006-01-20 |
US7253173B2 (en) | 2007-08-07 |
SE0203303D0 (en) | 2002-11-07 |
CN1711252A (en) | 2005-12-21 |
CA2502732A1 (en) | 2004-05-21 |
NO20052698D0 (en) | 2005-06-06 |
AR041895A1 (en) | 2005-06-01 |
UA80988C2 (en) | 2007-11-26 |
ZA200503556B (en) | 2006-08-30 |
US20070254890A1 (en) | 2007-11-01 |
IS7863A (en) | 2005-05-25 |
NZ539484A (en) | 2007-05-31 |
AU2003278665A1 (en) | 2004-06-07 |
AU2003278665B2 (en) | 2008-05-22 |
EP1562924A1 (en) | 2005-08-17 |
MXPA05004708A (en) | 2005-08-03 |
CN100415729C (en) | 2008-09-03 |
US20060122193A1 (en) | 2006-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0511531A (en) | compound, use of a compound, pharmaceutical composition, and methods for therapy of functional gastrointestinal disorders, irritable bowel syndrome and gastro-oesophageal reflux disorder and for preparing a compound | |
BRPI0514014A (en) | compound, use thereof, pharmaceutical composition, methods for the treatment of pain, anxiety, and parkinson's disease in a warm-blooded animal, and process for the preparation of a compound | |
BR0315995A (en) | Compound, use of a compound pharmaceutical composition, methods for the therapy of pain, gastrointestinal disorders, and anxiety in a warm-blooded animal, and process for preparing a compound | |
BRPI0514036A (en) | compound, pharmaceutically acceptable salts thereof, diastereomers, enantiomers or mixtures thereof, use of a compound, pharmaceutical composition, method for the therapy of depression in a warm-blooded animal, and process for preparing a compound | |
BRPI0407976A (en) | 2,5 and 2,6-substituted tetrahydroisoquinolines for use as 5-ht6 modulators | |
BRPI0511532A (en) | compound, use thereof, pharmaceutical composition, and, methods for the therapy of functional gastrointestinal disorders and irritable bowel syndrome in a warm-blooded animal, and for the preparation of a compound | |
BRPI0514032A (en) | compound, pharmaceutically acceptable salts thereof, diastereomers, enantiomers or mixtures thereof, use of a compound, pharmaceutical composition, method for the therapy of depression in a warm-blooded animal, and process for preparing a compound | |
BRPI0407811A (en) | pyrazolopyridine derivatives, process for their preparation, pharmaceutical composition and their use | |
BRPI0414780A (en) | compound, use thereof, pharmaceutical composition, and methods for pain therapy in a warm-blooded animal, and for preparing a compound | |
BRPI0911476A2 (en) | pyridazinone glycokinase activating compounds, pharmaceutical composition, use of the compounds, method for treating a disease and / or metabolic disorder and process for preparing the compounds | |
BR0314379A (en) | Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | |
BRPI0515897A (en) | compound, use thereof, pharmaceutical composition, and method for pain therapy in a warm-blooded animal, and for the preparation of a compound | |
BRPI0411246A (en) | compound, use thereof, pharmaceutical composition, and methods for pain therapy in a warm-blooded animal and for the preparation of a compound | |
BR0315320A (en) | Pharmaceutically acceptable compound or salts thereof, use of a compound, pharmaceutical composition, and methods for pain therapy in a warm-blooded animal and for producing a compound | |
BR0315998A (en) | Compound, use thereof, pharmaceutical composition, methods for pain therapy and functional gastrointestinal disorders in a warm-blooded animal, and process for preparing a compound | |
BRPI0411226A (en) | compound, use of a compound, pharmaceutical composition, and method for pain therapy in a warm-blooded animal, and for the preparation of a compound | |
BRPI0406614A (en) | Compound, use thereof, pharmaceutical composition, methods for pain therapy in a warm-blooded animal and for therapy of functional gastrointestinal disorders in a warm-blooded animal, and process for preparing a compound | |
BRPI0408689B8 (en) | benzenesulfonamide derivatives, method of preparation and use thereof for pain treatment | |
BR0214937A (en) | Process of preparation of echinocandin derivatives | |
BRPI0507511A (en) | compound, use of a compound, pharmaceutical composition, and process for preparing a compound | |
BRPI0506702A (en) | compound, use thereof, pharmaceutical composition, method for pain therapy, and functional gastrointestinal disorders in a warm-blooded animal, and process for preparing a compound | |
BRPI0408150A (en) | compound, its use and process for its preparation, methods for cancer treatment or prophylaxis and for producing a cell cycle inhibitory effect (anti - cell proliferation) in a warm blooded animal and pharmaceutical composition | |
BRPI0410353A (en) | compound, use of a compound, pharmaceutical composition, methods for pain and anxiety therapies in a warm-blooded animal, and process for preparing a compound | |
BRPI0406594A (en) | Compound, use thereof, pharmaceutical composition, methods for pain therapy and functional gastrointestinal disorders in a warm-blooded animal, and process for preparing a compound, process for preparing a compound. | |
BRPI0410347A (en) | compound, use of a compound, pharmaceutical composition, methods for the therapy of pain and functional gostrointestinal disorders in warm-blooded animals, and process for preparing a compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |